Recruiting

Building a Resource to Detect Pancreatic Cancer Early

Plain-English translation of NCT04970056 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

What is this trial?

The PRECEDE Consortium is a large research study collecting blood samples from about 20,000 people to build a shared resource for pancreatic cancer early detection and prevention. Researchers will study these samples over time to understand pancreatic cancer better and develop new ways to catch it before symptoms appear. This could eventually help save lives by finding the disease when it's easier to treat.

Pancreatic cancer is often found too late, when treatment options are limited. This study exists to create a research database and biobank that will help scientists discover new ways to detect pancreatic cancer earlier, especially in people with a higher genetic risk.

Do you qualify?

You likely qualify if…

you have a family history of pancreatic cancer, particularly multiple relatives affected or relatives diagnosed at a young age
you carry certain genetic mutations linked to increased pancreatic cancer risk (such as BRCA1, BRCA2, PALB2, or others)
you have been diagnosed with hereditary pancreatitis or certain hereditary cancer syndromes like Peutz-Jeghers syndrome or familial atypical moles and melanoma
you are age 35 or older (depending on your specific risk category), or younger if you meet other high-risk criteria
you are willing to donate blood samples every 6 to 12 months and allow researchers access to your medical records

You likely don't qualify if…

you have already been diagnosed with pancreatic cancer (unless you qualify for a specific cohort for people with a diagnosis)
you are unable or unwilling to provide blood samples or share your medical information
you do not meet any of the defined high-risk criteria for pancreatic cancer

What participation looks like

If you qualify, you will visit one of the participating research centers to have blood drawn and provide medical information. This process may repeat every 6 to 12 months as part of ongoing follow-up. Your samples will be stored and studied by researchers, and your doctors will continue providing your usual care. The study does not involve taking any medication — just blood donation and medical record sharing to help advance pancreatic cancer research.

AI-generated summary from trial data · Jul 12, 2026 · Not medical advice

Trial locations(60 sites)

United States

Mayo Clinic Arizona, Phoenix, Arizona

Honor Health Research Institute, Scottsdale, Arizona

Providence Health and Services, Burbank, California

City of Hope, Duarte, California

UC San Diego Moores Cancer Center, La Jolla, California